[Application and safety of thalidomide in the treatment of multiple myeloma].
Thalidomide is now regarded as one of the most promising salvage therapies for refractory or relapsed multiple myeloma. Appropriate use of this drug is indispensable to avoid repeating drug-induced disaster. Recently, its application has been expanded from refractory or relapsed cases also to untreated patients or post transplanted cases. Thus, it should be clarified which population of the Japanese patients with myeloma may truly benefit by this drug. Guideline, recently established by the Japanese Society of Clinical Hematology, has functioned for safety use of this drug. For future approval by Japanese government, strict but well-organized system for safety applicable to the clinical setting in Japan is necessary.
Hattori
Yutaka
Y
Division of Hematology, Department of Medicine, Keio University School of Medicine.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007564:Japan; D009101:Multiple Myeloma / Q000628:therapy*; D017410:Practice Guidelines as Topic; D017751:Safety Management; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects
D013792:Thalidomide